Mizuho Securities analyst Vamil Divan reiterated a Neutral rating and $148.00 price target on Eli Lilly (NYSE: LLY) following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor BaricitinibFebruary 12, 2020 5:54 AM Eli Lilly Canada (LLY) Announces Health Canada has approved TALTZ for Treatment of Active Ankylosing SpondylitisFebruary 11, 2020 6:52 AM Health Canada has approved TALTZ® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)February 11, 2020 6:45 AM Eagle Pharmaceuticals (EGRX) Receives Final FDA Approval for PEMFEXYFebruary 10, 2020 9:54 AM Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ (Pemetrexed for Injection)February 10, 2020 9:54 AM Pre-Open Stock Movers 2/10: (VTVT) (EPC) (TSLA) Higher (ABUS) (BHVN) (LLY) Lower (more...)February 10, 2020 9:21 AM Lilly (LLY) announces analysis performed by Washington University School of Medicine in DIAN-TU Study showed solanezumab did not meet primary endpointFebruary 10, 2020 6:29 AM Lilly Announces Topline Results for Solanezumab from the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) StudyFebruary 10, 2020 1:00 AM Lilly to Participate in Guggenheim Healthcare Talks Idea ForumFebruary 7, 2020 2:00 PM